MOR News and Press, MorphoSys AG From 08/26/21

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (...

- The decision by the European Commission is based on data from the L-MIND study evaluating Minjuvi in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Un...

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and license agreement with a subsidiary of InnoCare for tafasitamab in Gr...

The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q2 earnings call. For further details see: MorphoSys AG 2021 Q2 - Results - Earnings Call Presentation

MorphoSys AG (MOR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 ET Company Participants Julia Neugebauer - Senior Director, Investor Relations Jean-Paul Kress - Chief Executive Officer Sung Lee - Chief Financial Officer Roland Wandeler - Chief Operating Officer Malte Peters - Chief Re...

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q2 2021 Earnings Call Jul 30, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q2 2021 Earnings Call Transcript

MorphoSys (MOR): Q2 GAAP EPS of €0.61.Revenue of €38.2M (+100% Y/Y)Press Release For further details see: MorphoSys reports Q2 results

- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Pharma ...

IRSA Propiedades Comerciales (IRCP) -69%.Infinity Pharmaceuticals (INFI) -23% on Q2 earnings release and updates data from bladder and breast cancer trials.TRxADE HEALTH (MEDS) -20% on Q2 earnings release.Bit Digital (BTBT) -17%.Flora Growth (FLGC) -15% to f...

Dzmitry Dzemidovich/iStock via Getty Images MorphoSys (MOR) is trading ~4.8% lower after tightening its financial guidance for 2021, following a preliminary evaluation of its 2021 performance for the first six months. The company projects its group revenue for the year to be in...